As exemplars rather than confirmatory markers, TFF1 and B3GNT6 were repeatedly associated with Gefitinib resistance in LUAD, while OPALIN, LTF, IL2RA, and SLC17A7 were implicated in Temozolomide response in GBM, aligning with processes such as epithelial differentiation and angiogenesis. The gene discussed is SLC17A7; the disease is glioblastoma.